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Image in Focus
a University of Campinas (Unicamp), Hospital das Clínicas do Estado, Department of Dermatology and Pathology. Campinas, SP, Brazil.
b University of Campinas (Unicamp), Hospital das Clínicas do Estado, Department of Pathology. Campinas, SP, Brazil.
Pictures belong to the University of Campinas (Unicamp) compilation.
Figure 1. A – Skin-toned papules coalescing together into large plaques situated at the anterior and lateral sections 
of the neck. Also, the skin became flaccid; B – Yellowish, small papules grouped together in the flexural area (axillar); 
C – Weigert van Gieson stain by light microscopy shows material in the middle dermis grouped, fragmented, and 
twisted, which is consistent with elastic fibers; D – Von Kossa stain examined by light microscopy demonstrates that 
this material in the middle dermis blends in black, which represents calcium deposition. Therefore, as noticed in 
sequence, it shows calcified elastic fibers.
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Pseudoxanthoma elasticum (PXE) is an autosomal 
recessive disease of the connective tissue, which 
is characterized by mutations in the ABCC6 gene 
complex, located in chromosome 16p13. The precise 
prevalence is unknown, although it is estimated 
at 1/50,000 people. Diagnosing this condition is a 
challenge for physicians as the typical clinical features 
develop later in life, with cutaneous disorders being 
the earliest manifestation.1-3
Women are more often affected than men, in 
a ratio of 2:1. At birth, clinical manifestations are 
generally absent and the skin lesions start to develop 
in the first or second decade. As mentioned above, the 
cutaneous findings are frequently the first symptom of 
PXE. The most common areas affected are the lateral 
and posterior regions of the neck, the flexural areas 
(axillae, inguinal region, antecubital, and popliteal 
fossae), and the periumbilical area. The clinical feature 
is expressed by asymptomatic small papules (1-5 mm), 
yellowish or skin-tone, which blend together into large 
reticular plaques.4
Within the disease course, the patient starts 
presenting numerous cardiovascular manifestations, 
which include reduced peripheral pulse, hypertension, 
angina pectoris, and intermittent claudication. Since 
PXE patients may have premature atherosclerosis 
(caused by the mineralization and fragmentation of 
the elastic fibers of the medium-sized arteries and the 
aorta) they can also have early acute myocardial infarcts 
and cerebrovascular accidents. Furthermore, they have 
a higher cardiovascular risk as a result of alterations 
in lipoprotein composition and hypertriglyceridemia.4
The most important histological feature of PXE is 
elastorrhexis, a pattern at the middle dermis, which 
shows progressive mineralization and disintegration 
of the elastic fibers. Using light microscopy and 
relevant specific stains—such as Verhoeff-Van 
Gieson, and for calcium (Von Kossa or Alizarin Red)—
fragmented elastic fibers and mid-dermal calcification 
will be shown, respectively, which are essential for the 
diagnosis of PXE. This deterioration of the elastic fibers 
results in dermatologic, ophthalmologic, and vascular 
dysfunction.3,4
In 2010, Plomp et al.5 proposed new criteria 
(Table 1) for the diagnosis of PXE. Their requirements 
are listed below, but it is also necessary to exclude 
causes of PXE-like disease, such as sickle cell anemia, 
beta-thalassemia, and PXE-like phenotype with 
cutis laxa and multiple coagulation factor deficiency 
(when mutational analysis of ABCC6 is negative or 
not available).
Table 1. Proposed criteria for the diagnosis of PXE, (based on Plomp et al.5)
Major diagnostic Criteria Minor diagnostic criteria
1. Skin Eye
a. Yellowish papules and/or plaques on the lateral side of the neck and/or flexural areas of the body; One AS shorter than one disk diameter;
or or
b.
Increased of morphologically altered elastin with 
fragmentation, clumping and calcification of elastic 
fibers in a skin biopsy taken from clinically affected 
skin
One or more ‘comets’ or ‘wing signs’ in the retina
2. Eye Genetics
a. Peau d’orange of the retina A pathogenic mutation of one allele of the ABCC6 gene
or
b.
One or more angioid streaks (AS), each at least as 
long as one disk diameter. When in doubt, fluorescein 
or indocyanine green angiography of the fundus is 
needed for confirmation
3. Genetics
a. A pathogenic mutation of both alleles of the ABCC6 gene
or
b. A first degree-relative (parent, sib, child) who meets independently the diagnostic criteria for definitive PXE
Table reproduced with the consent and acknowledgment of  Jong PT5.
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Criteria for the diagnosis of PXE are:
a. Definitive diagnosis: The presence of two (or more) 
major criteria not belonging to the same category 
(skin, eye, genetics);
b. Probable diagnosis: The presence of two major 
eye or two major skin criteria, or the presence of 
one major criterion and one or more minor criteria 
not belonging to the same category as the major 
criterion;
c. Possible diagnosis: The presence of a single major 
criterion, or the presence of one or more minor 
criteria.
Despite the genetic progress in understanding 
this syndrome, no specific treatment is available. 
Some authors believe that a dietary supplementation 
with magnesium and a phosphate binder could have 
benefits in these patients, but this is still a controversial 
topic. Another study by Guo and colleagues6, utilizing 
Abcc6–/– mice, showed that starting a statin (atorvastatin) 
at age 4 weeks reduced lipid values and ameliorated 
vascular calcification (particularly at the higher dose)6. 
Some authors claim that statin is useful; however, further 
studies are needed.7
Nevertheless, the only fully accepted treatment is 
ocular manifestation, with the use of agents derived 
from the humanized monoclonal antibody to the 
vascular endothelial growth factor, which have shown 
effectiveness in choroidal manifestation.3
The above images refer to a 27-year-old woman 
who sought the dermatological clinic with a 15-year 
history of asymptomatic cervical and axillary cutaneous 
lesions. Her medical history included visual impairment, a 
former abortion after 12 weeks’ gestation, and a previous 
pregnancy with severe pre-eclampsia. On physical 
examination, the cervical and axillary regions presented a 
parchment-like elastic skin with yellowish papules clustered 
together forming plaques (Figure 1A and B). She also had 
loss of peripheral pulses and fundoscopy with bilateral 
angioid streaks. As suspected, the histopathological 
examination revealed grouped, fragmented, and twisted 
material in the middle dermis, which is consistent with 
calcified elastic fibers (Weirgt von Gieson [Figure 1C] and 
Von Kossa [Figure 1D]), and resulted in the diagnosis 
of PXE. However, we also excluded sickle cell anemia 
beta-thalassemia and coagulation factor deficiency.
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